Tezepelumab subcutaneous injection misses primary endpoint in patients with severe oral corticosteroid-dependent asthma

The SOURCE RCT failed to meet primary endpoint of statistically significant reduction in daily oral corticosteroids dose, without loss of asthma control, with tezepelumab (a novel inhibitor of thymic stromal lymphopoietin), versus placebo.

Source:

PharmaTimes